Hengrui Medicine Responds to FDA Delay on "Dual Ai" Combination Drug Approval
Hengrui Medicine has announced that it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the Biologics License Application for its combination therapy of camrelizumab injection and apatinib mesylate tablets. This combination is intended for the first-line treatment of patients with unresectable or metastatic hepatocellular carcinoma. This marks the third instance of the "Dual Ai" combination facing a delay in FDA approval. In response, Hengrui Medicine stated that the CRL does not raise concerns regarding the product's clinical research data, safety, or efficacy. The company emphasized that its internationalization strategy is progressing steadily, with multiple innovative drugs undergoing overseas research and development as planned. Hengrui Medicine plans to actively communicate with the FDA and its partner, Elevar Therapeutics, to determine the next steps for the submission process. The company expressed continued confidence in the long-term potential of the "Dual Ai" combination therapy for liver cancer treatment, citing robust clinical research data.
The FDA's repeated delays in approving Hengrui Medicine's "Dual Ai" combination therapy for liver cancer, despite the company's assurances about safety and efficacy, highlight the stringent regulatory hurdles for novel oncology treatments. While the CRL reportedly does not question the underlying clinical data, the repeated requests for further information or clarification suggest potential challenges in meeting the FDA's specific requirements for demonstrating clinical benefit or addressing complex manufacturing or quality control aspects. This situation underscores the critical importance of proactive and comprehensive engagement with regulatory bodies throughout the drug development lifecycle. For Hengrui Medicine, navigating these international regulatory pathways efficiently will be key to realizing the global commercial potential of its innovative pipeline and maintaining investor confidence amidst evolving market dynamics in the competitive oncology landscape.
AI-generated to prompt reflection — not editorial opinion, not advice, not a statement of fact. How this works.